Wednesday, January 30, 2013 10:48:02 PM
http://www.clinicaltrials.gov/ct2/show/NCT01272791?term=Bavituximab+OR+Peregrine&rank=1
Inclusion criteria.
Patients with histologically or cytologically documented stage IV ductal adenocarcinoma of the pancreas
In addition from the AACR poster presented last year we have this
So the treatment arm in the bavi pancreatic trial has worse PS scores than the control arm,
with 4 patients left to enroll, which will handicap the treatment arm. Then remember these too.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=83914184
Recent CDMO News
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
